A Phase 3 clinical trial update dated October 5, 2026 reports a change in status for a study involving octreotide as part of standard of care. The trial, registered as NCT05477576, is titled "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy."
The study is a Phase 3 trial and its current status is listed as active, not recruiting. This means the trial is ongoing but is no longer enrolling new participants at this time.
The trial compares RYZ101 against standard of care in patients with inoperable, somatostatin receptor positive, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). Eligible patients in this population have experienced disease progression following prior 177Lu-SSA therapy.
No results or outcome data have been reported as part of this update. The status change reflects only the enrollment and operational stage of the trial as of the listed date. Octreotide's role in this trial is as part of the standard of care comparator arm, consistent with its approved regulatory status.
Readers seeking general background on octreotide can consult the compound overview for additional context.